Abstract
Sulfation and glucuronidation, the major routes of metabolism of troglitazone, an antidiabetic agent, were examined in vitro using hepatic cytosol and microsomes prepared from KK mice, an animal model of non-insulin-dependent diabetes mellitus. Stereoselectivity was observed for both conjugation reactions, and the metabolic intrinsic clearance of glucuronidation was about 3- to 100-fold higher than that of sulfation for each stereoisomer. In addition, the metabolic intrinsic clearance of glucuronidation exhibited an 8-fold difference among stereoisomers. The predicted metabolic clearance for each stereoisomer, calculated from thein vitro data based on a dispersion model, was comparable to the measured metabolic clearance in vivo, ranging from 27 to 93%. We also attempted to predict the in vivo metabolic clearance from in vitrometabolism data, to investigate species differences in the stereoselectivity of the conjugation reactions in normal animals,i.e., ddY mice and rats. For ddY mice the in vivo hepatic glucuronidation clearance was 170-fold higher than the corresponding sulfation clearance, whereas for rats the sulfation clearance was 6-fold higher than the glucuronidation clearance. The hepatic sulfation clearance in mice and rats predicted from in vitro metabolism data was 5.3- and 1.1-fold higher, respectively, than that in vivo, calculated from the plasma disposition of parent drug and biliary excretion of metabolites. For glucuronidation, the predicted values in mice and rats were 1.0- and 0.33-fold higher, respectively. These results suggest that semiquantitative extrapolation of in vitrostereoselective metabolism of troglitazone, by conjugation, to thein vivo situation is possible.
Footnotes
-
Send reprint requests to: Takashi Izumi, Analytical and Metabolic Research Laboratories, Sankyo Co., 2–58, Hiromachi 1-Chome, Shinagawa-ku, Tokyo 140, Japan.
- Abbreviations:
- CLH
- hepatic plasma clearance
- CLH,Glu.
- hepatic plasma clearance for glucuronidation
- CLH,Sulf.
- hepatic plasma clearance for sulfation
- CLtot
- total-body plasma clearance
- CLuint
- metabolic intrinsic clearance
- CLuint,Glu.
- metabolic intrinsic clearance for glucuronidation
- CLuint,Sulf.
- metabolic intrinsic clearance for sulfation
- Cu
- unbound concentration
- fu
- unbound fraction
- HPFA
- high-performance frontal analysis
- HPLC
- high-performance liquid chromatography
- PAPS
- adenosine-3′-phosphate-5′-phosphosulfate
- UDPGA
- uridine-5′-diphosphoglucuronic acid
- Received February 6, 1996.
- Accepted November 22, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|